Macrophage Polarization in the Perivascular Fat Was Associated With Coronary Atherosclerosis

Carregando...
Imagem de Miniatura
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Citação
JOURNAL OF THE AMERICAN HEART ASSOCIATION, v.11, n.6, article ID e023274, 30p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Inflammation of the perivascular adipose tissue (PvAT) may be related to atherosclerosis; however, the association of polarized macrophages in the pericoronary PvAT with measurements of atherosclerosis components in humans has not been fully investigated. Methods and Results Coronary arteries were dissected with surrounding PvAT. We evaluated the percentage of arterial obstruction, intima-media thickness, fibrous cap thickness, plaque components, and the number of vasa vasorum. The number of proinflammatory (M1) and anti-inflammatory (M2) macrophages in the periplaque and control PvAT were evaluated using immunohistochemistry. Regression models adjusted for sociodemographic and clinical variables were used. In 319 segments from 82 individuals, we found a correlation of the M1/M2 macrophage density ratio with an increase in arterial obstruction (P=0.02) and lipid content (P=0.01), and a decrease in smooth muscle cells (P=0.02). M1 and the ratio of M1/M2 macrophages were associated with an increased risk of thrombosis (P=0.03). In plaques with thrombosis, M1 macrophages were correlated with a decrease in fibrous cap thickness (P=0.006), an increase in lipid content (P=0.008), and the number of vasa vasorum in the adventitia layer (P=0.001). M2 macrophages were correlated with increased arterial obstruction (P=0.01), calcification (P=0.02), necrosis (P=0.03) only in plaques without thrombosis, and decrease of the number of vasa vasorum in plaques with thrombosis (P=0.003). Conclusions M1 macrophages in the periplaque PvAT were associated with a higher risk of coronary thrombosis and were correlated with histological components of plaque progression and destabilization. M2 macrophages were correlated with plaque size, calcification, necrotic content, and a decrease in the number of vasa vasorum in the adventitia layer.
Palavras-chave
atherosclerosis, coronary artery disease, inflammation, macrophages, pericoronary adipose tissue
Referências
  1. Andrade RA., 2017, PROCESSAMENTO IMAGEN
  2. Chatterjee TK, 2009, CIRC RES, V104, P541, DOI 10.1161/CIRCRESAHA.108.182998
  3. Cho KY, 2013, J STROKE CEREBROVASC, V22, P910, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.020
  4. Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218
  5. Farfel JM, 2013, NEUROLOGY, V81, P650, DOI 10.1212/WNL.0b013e3182a08f1b
  6. Farias-Itao DS, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013793
  7. Farias-Itao DS, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.6340
  8. Fernandez-Friera L, 2019, J AM COLL CARDIOL, V73, P1371, DOI 10.1016/j.jacc.2018.12.075
  9. Ferretti Renata Eloah de Lucena, 2010, Dement. neuropsychol., V4, P138, DOI 10.1590/S1980-57642010DN40200011
  10. Fitzgibbons TP, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124859
  11. Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
  12. Gurses KM, 2017, J CARDIOL, V69, P851, DOI 10.1016/j.jjcc.2016.08.016
  13. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  14. Hedgire S, 2018, RADIOLOGY, V287, P808, DOI 10.1148/radiol.2017171568
  15. Hirata Y, 2011, J AM COLL CARDIOL, V58, P248, DOI 10.1016/j.jacc.2011.01.048
  16. Ito H, 2020, CIRC J, V84, P769, DOI 10.1253/circj.CJ-19-0914
  17. Kanaji Y, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016504
  18. Khallou-Laschet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008852
  19. Kitagawa T, 2015, ATHEROSCLEROSIS, V243, P293, DOI 10.1016/j.atherosclerosis.2015.09.013
  20. Konishi M, 2010, ATHEROSCLEROSIS, V213, P649, DOI 10.1016/j.atherosclerosis.2010.10.007
  21. Kroll L, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020356
  22. Libby P, 2015, CIRC RES, V116, P307, DOI 10.1161/CIRCRESAHA.116.301313
  23. Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
  24. Margaritis M, 2013, CIRCULATION, V127, P2209, DOI 10.1161/CIRCULATIONAHA.112.001133
  25. McClain J, 2013, OBESITY, V21, P1056, DOI 10.1002/oby.20090
  26. McKenney-Drake ML, 2017, ANN THORAC SURG, V103, P1622, DOI 10.1016/j.athoracsur.2016.11.034
  27. Mikami T, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018905
  28. Montanaro M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010395
  29. NAKATANI S, 1995, CIRCULATION, V91, P2904, DOI 10.1161/01.CIR.91.12.2904
  30. Narula J, 2013, J AM COLL CARDIOL, V61, P1041, DOI 10.1016/j.jacc.2012.10.054
  31. Numaguchi R, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011147
  32. Ohman MK, 2011, ATHEROSCLEROSIS, V219, P33, DOI 10.1016/j.atherosclerosis.2011.07.012
  33. Ohyama K, 2018, J AM COLL CARDIOL, V71, P414, DOI 10.1016/j.jacc.2017.11.046
  34. Oikonomou EK, 2018, LANCET, V392, P929, DOI 10.1016/S0140-6736(18)31114-0
  35. Pierzynova A, 2019, NUTR METAB CARDIOVAS, V29, P946, DOI 10.1016/j.numecd.2019.05.063
  36. Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
  37. Shimabukuro M, 2013, ARTERIOSCL THROM VAS, V33, P1077, DOI 10.1161/ATVBAHA.112.300829
  38. Shioi A, 2018, J ATHEROSCLER THROMB, V25, P294, DOI 10.5551/jat.RV17020
  39. Skiba DS, 2017, BRIT J PHARMACOL, V174, P4055, DOI 10.1111/bph.13685
  40. Suemoto CK, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002267
  41. Suemoto CK, 2011, STROKE, V42, P3614, DOI 10.1161/STROKEAHA.111.628156
  42. Takaoka M, 2010, ARTERIOSCL THROM VAS, V30, P1576, DOI 10.1161/ATVBAHA.110.207175
  43. Tanaka K, 2011, ATHEROSCLEROSIS, V215, P366, DOI 10.1016/j.atherosclerosis.2011.01.016
  44. Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
  45. Uiversity of California Los Angeles: Institute for Digital Research & Education, REGR STAT CHAPT 4 OL
  46. University of California Los Angeles: Statistical Consulting Group., CAN US COUNTF CHOOS
  47. Verhagen SN, 2014, ATHEROSCLEROSIS, V233, P242, DOI 10.1016/j.atherosclerosis.2013.12.005
  48. Veseli BE, 2017, EUR J PHARMACOL, V816, P3, DOI 10.1016/j.ejphar.2017.05.010
  49. World Health Organization, 2021, CARD DIS CVDS
  50. Yahagi K, 2016, NAT REV CARDIOL, V13, P79, DOI 10.1038/nrcardio.2015.164